EA
NBIX icon

Emerald Advisers’s Neurocrine Biosciences NBIX Stock Holding History

Emerald Advisers’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-100,844
Closed -$4.64M – 247
2017
Q2 		$4.64M Sell
100,844
-205,026
-67% -$9.94M 0.19% 114
2017
Q1 		$13.2M Sell
305,870
-8,777
-3% -$376K 0.54% 74
2016
Q4 		$12.2M Buy
314,647
+57,818
+23% +$2.62M 0.52% 78
2016
Q3 		$13M Buy
256,829
+8,710
+4% +$434K 0.58% 66
2016
Q2 		$11.3M Sell
248,119
-65,425
-21% -$3.01M 0.54% 63
2016
Q1 		$12.4M Buy
313,544
+10,337
+3% +$410K 0.6% 62
2015
Q4 		$17.2M Buy
303,207
+36,180
+14% +$1.84M 0.81% 32
2015
Q3 		$10.6M Sell
267,027
-198,419
-43% -$9.59M 0.55% 61
2015
Q2 		$22.2M Buy
465,446
+3,193
+0.7% +$135K 1.06% 19
2015
Q1 		$17.5M Sell
462,253
-78,720
-15% -$2.82M 0.88% 26
2014
Q4 		$12.1M Buy
540,973
+206,790
+62% +$3.92M 0.64% 47
2014
Q3 		$5.24M Buy
334,183
+94,193
+39% +$1.41M 0.31% 105
2014
Q2 		$3.56M Buy
239,990
+1,580
+0.7% +$22.3K 0.2% 154
2014
Q1 		$3.84M Buy
+238,410
New +$4.08M 0.22% 143

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Emerald Advisers's NBIX Position: Q3 2017 in Review

Emerald Advisers sold out of Neurocrine Biosciences (NBIX) in Q3 2017, closing a stake of 100,844 shares — an estimated $4.64M sold.

Emerald Advisers first reported a position in NBIX in Q1 2014 and held it in 14 quarters. The position peaked at $22.2M in Q2 2015. 223 funds tracked by Wall St. Rank hold NBIX as of Q3 2017.

  • Emerald Advisers reported no remaining Neurocrine Biosciences position as of Q3 2017 after selling out during the quarter.
  • Emerald Advisers sold 100,844 Neurocrine Biosciences shares in Q3 2017, an estimated $4.64M.
  • Emerald Advisers first reported a position in Neurocrine Biosciences in Q1 2014 and held it in 14 quarters.
  • Emerald Advisers's Neurocrine Biosciences position peaked at $22.2M in Q2 2015.
  • 223 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2017.

Based on Emerald Advisers's 13F filing for Q3 2017, filed 30 Oct 2017.